Emerald Advisers LLC Buys 83,083 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Emerald Advisers LLC raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 22.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 454,794 shares of the company's stock after purchasing an additional 83,083 shares during the quarter. TransMedics Group accounts for about 1.4% of Emerald Advisers LLC's investment portfolio, making the stock its 21st biggest position. Emerald Advisers LLC owned about 1.34% of TransMedics Group worth $30,599,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TMDX. NBC Securities Inc. bought a new position in shares of TransMedics Group during the 1st quarter worth about $25,000. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group during the 4th quarter worth about $31,000. AlphaQuest LLC bought a new position in shares of TransMedics Group during the 4th quarter worth about $52,000. Sava Infond d.o.o. bought a new position in shares of TransMedics Group during the 4th quarter worth about $94,000. Finally, GAMMA Investing LLC increased its holdings in shares of TransMedics Group by 551.7% during the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after purchasing an additional 1,324 shares during the period. Institutional investors own 99.67% of the company's stock.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 5,000 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director directly owned 2,866 shares of the company's stock, valued at approximately $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by insiders.

TransMedics Group Price Performance

TransMedics Group stock traded down $2.36 during trading hours on Wednesday, hitting $113.32. 714,535 shares of the stock were exchanged, compared to its average volume of 1,379,124. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. The stock has a market capitalization of $3.83 billion, a P/E ratio of 85.06 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The business's 50-day moving average is $126.43 and its two-hundred day moving average is $91.41.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company's quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.35 earnings per share. Equities research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TMDX has been the topic of several research reports. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Oppenheimer upped their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Canaccord Genuity Group upped their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $129.88.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.